Last reviewed · How we verify
Benfluramate (BENFLUOREX)
Benfluorex, a marketed drug by an unspecified company, targets Type 2 diabetes mellitus in obese patients through a unique mechanism of activating mitochondrial uncoupling proteins. Its key strength lies in improving insulin sensitivity and increasing energy expenditure, distinguishing it from off-patent competitors like repaglinide and nateglinide. The primary risk is the upcoming key patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | BENFLUOREX |
|---|---|
| Drug class | benfluorex |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1974 |
Approved indications
- Type 2 diabetes mellitus in obese
Common side effects
Key clinical trials
- Study of the Effect of the Benfluorex (NA)
- Impact of Benfluorex Versus Metformin on Glucose Control and Insulin Secretion in Chinese Type 2 Diabetic Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Benfluramate CI brief — competitive landscape report
- Benfluramate updates RSS · CI watch RSS